Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren’s syndrome, as well as in a Phase 2 clinical trial for myopia control in young children. Sunhawk Vision Biotech, Inc. was founded in 2019 and is based in Taipei, Taiwan.